Story file
Smithers enters peptide testing by buying ACS Laboratory
A testing group founded in 1925 has bought the Florida lab now trading as ACS Peptide Testing Labs. The release is worth reading for what it does not name.
A name that signs assay reports in this category has changed hands. In a release datelined “(Fairlawn, Ohio, USA) August 28, 2026”, Smithers announced its entrance into peptide testing services through the acquisition of ACS Laboratory, near Tampa. The lab now trades as ACS Peptide Testing Labs, “a Smithers company”. Rubber World carried the announcement on 1 September. Smithers’ own newsroom returned 403 to this desk on the day of writing.
The release discloses no terms and no closing date.
Who was put on the record
The first executive quoted is AJ McCardell, President of Smithers’ Cannabis Testing Services Division. That is the analytical lineage arriving in research-peptide certificate work. CEO Michael Hochschwender supplies the second quote. Set beside the trade-press account — which leads on national hemp testing, peptides second, Florida cannabis testing still pending a state approval — one transaction is being told two ways to two audiences.
What the release names, and does not
It names no accreditation body, no accreditation scope and no certificate number. The lab’s homepage carries a strip of five badges, labelled in the page’s own markup “Accreditations and standards”, each a label with a subtitle: “Validated Methods” / “ICH & USP referenced”; “ASTM D8558” / “Peptide Standard”; “ASTM F49” / “Committee Member”; “DEA Registered” / “Controlled Analysis”; “US-Based Lab” / “Sun City Center, FL”. None names an accrediting body, a scope or a certificate number, and a registration is not an accreditation. This desk checked none of the five against a register and asserts none; the list records what the page publishes, not what the laboratory holds.
One badge is checkable against a primary source, and it fails. ASTM D8558-24 is the Standard Guide for verification of a certificate of authentication used to track products through their supply chain by utilizing blockchain technology, owned by Committee F49, subcommittee F49.06. It concerns NFTs, RFID tags and QR codes. It is not a peptide standard.
The quote panel beneath the release — a site-wide module, not text of the release — offers a “Traceable COA with chromatograms and method parameters”. Chromatograms and method parameters are what a summary purity figure leaves out, so the wording promises more than a percentage. It is still a promise rather than a specimen.
What a buyer does with this
This desk noted in August that suppliers had started competing on whose laboratory signed the report. Consolidation is the next move, with a practical consequence: the letterhead on a stack of existing certificates changes while the lot numbers underneath do not. Ask which entity issued the report you hold, whether it will still confirm the identifier on it, and under what scope. The release answers none of that.
Materials in this category are supplied for laboratory research use only, and nothing above concerns their use in humans. A change of ownership at an analysing laboratory is a documentation event, and the kind this market records worst.